Horus Pharma expands distribution in North Africa and the Middle East
Ella Day | August 8, 2025 | News story | Mergers and Acquisitions, Research and Development | Corporate, Horus Pharma, Opthalmology, distribution agreement
Ophthalmology company, Horus Pharma, based in Nice, France, has extended its global presence through new distribution agreements across eight countries in North Africa, and the Near and Middle East. The company will now operate in Tunisia, Lebanon, Qatar, Kuwait, Bahrain, Saudi Arabia, the United Arab Emirates and Oman – bringing its total footprint to over 30 countries.
This expansion marks a new stage in Horus Pharma’s international growth strategy, as it positions the region as a key area for future development. According to industry projections, the combined ophthalmology market in Africa and the Near and Middle East was valued at $3bn in 2024 and is expected to reach $4.5bn by 2032.
Several factors are driving this growth, including an ageing population, rising prevalence of eye conditions such as cataracts and diabetic retinopathy, and increased adoption of medical technologies like optical coherence tomography and telemedicine.
“With these new partnerships, we are now established in nine countries in the Near and Middle East,” said Nicolas Claret, international director at Horus Pharma. “This diverse and rapidly developing region represents a major area of development for us, in which we wish to promote French expertise in eye health.”
Horus Pharma currently generates 15% of its revenue outside France and aims to double this figure within three years. Its international model combines distribution agreements, joint ventures and subsidiary creation, with a focus on adapting to local market conditions.
Ella Day
8/8/25
